MX2020009496A - Metodo para tratar asma o enfermedad alergica. - Google Patents
Metodo para tratar asma o enfermedad alergica.Info
- Publication number
- MX2020009496A MX2020009496A MX2020009496A MX2020009496A MX2020009496A MX 2020009496 A MX2020009496 A MX 2020009496A MX 2020009496 A MX2020009496 A MX 2020009496A MX 2020009496 A MX2020009496 A MX 2020009496A MX 2020009496 A MX2020009496 A MX 2020009496A
- Authority
- MX
- Mexico
- Prior art keywords
- allergic disease
- treating asthma
- agent
- notch4
- asthma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643476P | 2018-03-15 | 2018-03-15 | |
| US201862652630P | 2018-04-04 | 2018-04-04 | |
| US201862659379P | 2018-04-18 | 2018-04-18 | |
| PCT/US2019/022493 WO2019178488A1 (en) | 2018-03-15 | 2019-03-15 | Method for treating asthma or allergic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009496A true MX2020009496A (es) | 2021-02-26 |
Family
ID=67908052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009496A MX2020009496A (es) | 2018-03-15 | 2019-03-15 | Metodo para tratar asma o enfermedad alergica. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210278418A1 (enExample) |
| EP (1) | EP3765025A4 (enExample) |
| JP (2) | JP2021518345A (enExample) |
| KR (1) | KR20200136939A (enExample) |
| CN (1) | CN112188901A (enExample) |
| AU (1) | AU2019236244B2 (enExample) |
| BR (1) | BR112020018810A2 (enExample) |
| CA (1) | CA3094143A1 (enExample) |
| MX (1) | MX2020009496A (enExample) |
| RU (1) | RU2020133768A (enExample) |
| WO (1) | WO2019178488A1 (enExample) |
| ZA (1) | ZA202005720B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230212274A1 (en) * | 2020-02-21 | 2023-07-06 | The Children's Medical Center Corporation | Method for treating asthma or allergic disease |
| CA3182210A1 (en) * | 2020-06-12 | 2021-12-16 | Talal CHATILA | Methods and compositions for treating coronavirus infectious disease |
| CN116473968A (zh) * | 2022-01-24 | 2023-07-25 | 华中科技大学 | Ezh2特异性抑制剂在治疗哮喘的用途 |
| JP2025533355A (ja) | 2022-10-05 | 2025-10-06 | アルシーア セラピューティクス, インコーポレイテッド | 気道炎症を処置するためのnotch4抗体、組成物および方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2573565A1 (en) * | 2004-07-22 | 2006-02-02 | Duska Scientific Co. | Method of diagnosing, monitoring and treating pulmonary diseases |
| US20060211079A1 (en) * | 2005-02-18 | 2006-09-21 | Hazen Stanley L | Systemic markers for asthma and analogous diseases |
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| WO2007028110A2 (en) * | 2005-09-01 | 2007-03-08 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| US10206941B2 (en) * | 2013-07-09 | 2019-02-19 | President And Fellows Of Harvard College | Venule endothelial cell genes and uses thereof |
| GB201416832D0 (en) * | 2014-09-24 | 2014-11-05 | Glaxosmithkline Plc | Methods of treatment |
| WO2019036613A1 (en) * | 2017-08-18 | 2019-02-21 | Ionis Pharmaceuticals, Inc. | MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS |
-
2019
- 2019-03-15 EP EP19767845.1A patent/EP3765025A4/en not_active Withdrawn
- 2019-03-15 CA CA3094143A patent/CA3094143A1/en active Pending
- 2019-03-15 MX MX2020009496A patent/MX2020009496A/es unknown
- 2019-03-15 RU RU2020133768A patent/RU2020133768A/ru unknown
- 2019-03-15 BR BR112020018810-7A patent/BR112020018810A2/pt not_active Application Discontinuation
- 2019-03-15 KR KR1020207029275A patent/KR20200136939A/ko not_active Ceased
- 2019-03-15 WO PCT/US2019/022493 patent/WO2019178488A1/en not_active Ceased
- 2019-03-15 US US16/979,382 patent/US20210278418A1/en not_active Abandoned
- 2019-03-15 JP JP2020549027A patent/JP2021518345A/ja active Pending
- 2019-03-15 AU AU2019236244A patent/AU2019236244B2/en active Active
- 2019-03-15 CN CN201980032328.2A patent/CN112188901A/zh active Pending
-
2020
- 2020-09-15 ZA ZA2020/05720A patent/ZA202005720B/en unknown
-
2024
- 2024-02-28 JP JP2024028289A patent/JP2024063095A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3765025A1 (en) | 2021-01-20 |
| KR20200136939A (ko) | 2020-12-08 |
| AU2019236244A1 (en) | 2020-10-22 |
| ZA202005720B (en) | 2022-01-26 |
| WO2019178488A1 (en) | 2019-09-19 |
| JP2024063095A (ja) | 2024-05-10 |
| CN112188901A (zh) | 2021-01-05 |
| AU2019236244B2 (en) | 2025-02-20 |
| BR112020018810A2 (pt) | 2021-02-17 |
| US20210278418A1 (en) | 2021-09-09 |
| JP2021518345A (ja) | 2021-08-02 |
| EP3765025A4 (en) | 2022-03-09 |
| CA3094143A1 (en) | 2019-09-19 |
| RU2020133768A (ru) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018263868A1 (en) | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| EP4349997A3 (en) | Anti-garp antibody | |
| PH12019501533A1 (en) | Tigit-and light-based chimeric proteins | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| PH12019501706A1 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| MX2021005394A (es) | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| EP4316517A3 (en) | Combination therapy against cancer | |
| EP4234013A3 (en) | Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3 | |
| MX2020009496A (es) | Metodo para tratar asma o enfermedad alergica. | |
| WO2018226992A8 (en) | Tau aggregation inhibitors | |
| MX2020008122A (es) | Anticuerpos anti-pd-1. | |
| HK1254432A1 (zh) | 用於治疗纤维性疾病的方法和组合物 | |
| EP4445913A3 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| MX2022011972A (es) | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. | |
| HK1259083A1 (zh) | 用於治疗系统性肥大细胞增多症的方法和组合物 | |
| WO2019200314A3 (en) | Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| NZ762312A (en) | Anti-pacap antibody | |
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
| ZA201900070B (en) | Antibodies with low immunogenicity and uses thereof |